Phone reminders to help with glaucoma eye drops
Part of Eyes & vision clinical trials.
This trial tests if personalized reminders sent to your phone can help you remember to use your glaucoma eye drops and better control eye pressure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have primary open-angle glaucoma in at least one eye.
- You are currently using at least one prescription eye drop for glaucoma.
- You have a mobile phone that can receive text messages or WhatsApp messages.
- You are willing to follow study procedures and attend follow-up visits for 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called REGN22530 for people with mild to moderate primary open-angle glaucoma or ocular hypertension (high eye pressure). The goal is to see if it can safely lower eye pressure and protect vision.
This study tests a new eye drop against an existing one to see which better lowers eye pressure in people with open-angle glaucoma or ocular hypertension. You may be able to join if you have high eye pressure in both eyes that needs treatment and you are at least 18 years old.
This study tests whether reminders and extra check-ins help people with glaucoma stay on track with their eye drops and clinic visits. It aims to see if these supports keep eyes healthier by preventing missed drops and appointments.
This study tests whether text message reminders can help people check and manage their blood pressure at home. If you live independently in affordable housing and are 40 or older, this could be a simple way to keep your heart healthy.
This study tests a smart cap for your eye drop bottle that records when you use your drops. It is for people with glaucoma who sometimes miss doses and want to track their adherence with a phone app.
This study tests an eye drop (G01) for people with primary open-angle glaucoma that is getting worse despite current treatments. It aims to see if G01 can safely slow down or stop the progression of glaucoma.
Hear when a new Primary Open-Angle Glaucoma (POAG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.